Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen GJJE, Baumgartner F, Heider M, Patra U, Holz M, Braune J, Kaiser M, Schäffer I, Bamopoulos SA, Ramberger E, Murgai A, Ng YLD, Demel UM, Laue D, Liebig S, Krüger J, Janz M, Nogai A, Schick M, Mertins P, Müller S, Bassermann F, Krönke J, Keller U, Wirth M. Heynen GJJE, et al. Among authors: bassermann f. Blood Adv. 2023 Feb 28;7(4):469-481. doi: 10.1182/bloodadvances.2022007875. Blood Adv. 2023. PMID: 35917568 Free PMC article.
Cks1 promotion of S phase entry and proliferation is independent of p27Kip1 suppression.
Hoellein A, Graf S, Bassermann F, Schoeffmann S, Platz U, Hölzlwimmer G, Kröger M, Peschel C, Oostendorp R, Quintanilla-Fend L, Keller U. Hoellein A, et al. Among authors: bassermann f. Mol Cell Biol. 2012 Jul;32(13):2416-27. doi: 10.1128/MCB.06771-11. Epub 2012 Apr 16. Mol Cell Biol. 2012. PMID: 22508990 Free PMC article.
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Eichner R, Heider M, Fernández-Sáiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platzbecker U, Germing U, Langer C, Knop S, Einsele H, Peschel C, Haass C, Keller U, Schmid B, Götze KS, Kuster B, Bassermann F. Eichner R, et al. Among authors: bassermann f. Nat Med. 2016 Jul;22(7):735-43. doi: 10.1038/nm.4128. Epub 2016 Jun 13. Nat Med. 2016. PMID: 27294876
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.
Heider M, Eichner R, Stroh J, Morath V, Kuisl A, Zecha J, Lawatscheck J, Baek K, Garz AK, Rudelius M, Deuschle FC, Keller U, Lemeer S, Verbeek M, Götze KS, Skerra A, Weber WA, Buchner J, Schulman BA, Kuster B, Fernández-Sáiz V, Bassermann F. Heider M, et al. Among authors: bassermann f. Mol Cell. 2021 Mar 18;81(6):1170-1186.e10. doi: 10.1016/j.molcel.2020.12.046. Epub 2021 Feb 10. Mol Cell. 2021. PMID: 33571422 Free PMC article.
Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
Heider M, Nickel K, Högner M, Bassermann F. Heider M, et al. Among authors: bassermann f. Oncol Res Treat. 2021;44(12):672-681. doi: 10.1159/000520312. Epub 2021 Nov 8. Oncol Res Treat. 2021. PMID: 34749378 Free PMC article. Review.
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Stroh J, Seckinger A, Heider M, Rudelius M, Eichner R, Schick M, Slawska J, Emde-Rajaratnam M, Salwender H, Bertsch U, Goldschmidt H, Weisel K, Scheid C, Keller U, Hose D, Bassermann F. Stroh J, et al. Among authors: bassermann f. Blood Adv. 2022 Jan 25;6(2):515-520. doi: 10.1182/bloodadvances.2021005532. Blood Adv. 2022. PMID: 34768284 Free PMC article.
179 results